ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,296 GBX | -0.87% |
|
+1.54% | +16.00% |
| 05-24 | Innate Pharma: five abstracts selected for ASCO | CF |
| 05-24 | Adherium Partners with AstraZeneca for Hailie Smartinhaler Trial | MT |
ETFs positioned on AstraZeneca PLC
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 5.39% | 200 M€ | +18.18% | ||
| 5.17% | 17 M€ | +7.15% | - | |
| 4.89% | 693 M€ | +13.07% | ||
| 4.11% | 88 M€ | +10.37% | - | |
| 3.47% | 232 M€ | +14.08% | ||
| 2.74% | 4 M€ | -.--% | - | |
| 2.57% | 6 M€ | -.--% | ||
| 2.53% | 7 M€ | +9.75% | - | |
| 2.53% | 664 M€ | +10.01% | ||
| 1.54% | 29 M€ | +8.37% | - | |
| 1.51% | 2 M€ | -.--% | - | |
| 1.51% | 2 M€ | +9.19% | - | |
| 1.26% | 12 M€ | +15.09% | - | |
| 1.19% | 48 M€ | +9.74% | ||
| 1.16% | 10 M€ | -3.35% | - | |
| 0.97% | 7 M€ | +5.87% | - | |
| 0.89% | 32 M€ | +7.50% | - | |
| 0.86% | 276 M€ | +11.40% | - | |
| 0.70% | 264 M€ | -.--% | - | |
| 0.69% | 187 M€ | +10.85% | - | |
| 0.69% | 477 M€ | +12.73% | ||
| 0.57% | 205 M€ | -.--% | ||
| 0.54% | 284 M€ | -.--% | ||
| 0.51% | 23 M€ | -.--% | - | |
| 0.51% | 786 M€ | -.--% | ||
| 0.50% | 206 M€ | -.--% | ||
| 0.48% | 727 M€ | +8.98% | ||
| 0.43% | 283 M€ | +21.92% |
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
156.7
USD
Average target price
170.1
USD
Spread / Average Target
+8.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.00% | 243B | |
| +38.51% | 727B | |
| +33.05% | 599B | |
| -6.23% | 354B | |
| +18.78% | 328B | |
| +1.35% | 277B | |
| +8.09% | 205B | |
| -5.77% | 203B | |
| +6.19% | 164B | |
| +0.31% | 164B |
- Stock Market
- Equities
- AZN Stock
- Funds and ETFs AstraZeneca PLC
